Turmeric May Induce Cell Death in Esophageal Cancer Sans Apoptosis
Turmeric, or curcumin (diferuloylmethane), may be a favorable agent for the prevention and treatment of esophageal cancer, according to researchers at the Cork Cancer Research Center and Mercy University Hospital in Cork, Ireland. The authors noted that turmeric was able to induce cell death by a mechanism that is not reliant on apoptosis induction.
Turmeric, or curcumin (diferuloylmethane), may be a favorable agent for the prevention and treatment of esophageal cancer, according to researchers at the Cork Cancer Research Center and Mercy University Hospital in Cork, Ireland. The authors noted that turmeric was able to induce cell death by a mechanism that is not reliant on apoptosis induction.
They examined the effects of curcumin on esophageal cancer cell lines, focusing on mitotic catastrophe, apoptosis, and autophagy. They found that curcumin-responsive cells accumulated poly-ubiquitinated proteins and cyclin B, which was consistent with a disturbance of the ubiquitin-proteasome system.
"This effect...may be responsible for the mitotic disturbances and consequent cytotoxicity of [curcumin]," they wrote (Br J Cancer online, October 6, 2009).
Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer
January 20th 2024Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Progress Reported in Advanced Esophageal Cancer
June 7th 2010Meeting podcast: Listen to nationally regarded GI cancer specialist and clinical researcher, Peter C. Enzinger, MD, Assistant Professor of Medicine, Dana-Farber Cancer Institute, discuss new developments and trends in the management of esophageal cancer.
Lenvatinib Combo Demonstrates Safety, Activity in Metastatic ESCC
October 23rd 2023Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.
